Bone turnover markers

There are 222 papers on bone turnover markers in aging research: 56 trials and 58 observational studies in people, 32 in animals, 66 reviews. The newest story, Nov 17, 2026: “Loneliness linked to poorer bone health in older men”.

Biomarker

222 papers study it212 more mention it77 findings

19 new papers in 30 daysSee all 434 papers on bone turnover markers

“We discovered several variants in ADRB1, ADRB2, and HDAC4 which showed significant pharmacogenetic effects with BMD at multiple sites and with BTMs.”
Pharmacogenetic and microRNA mechanisms of beta blocker use on boneJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2024doi:10.1093/jbmr/zjae200
  • Human trial56
  • Humans58
  • Animals32
  • In silico1

Interventions

32

Cholecalciferol

no changein humans6upin humans1

7 studies
  1. Cholecalciferol showed no clear effect on bone turnover markers in humans (vitamin D insufficiency).

    “While BTMs were relatively stable.”

    Human trialvitamin D insufficiency400 or 800 IU/day26 weeksfemales

    Assessment of the effect of routine-dose vitamin D3 supplementation in Chinese women of childbearing age with vitamin D insufficiency

    European journal of nutrition

  2. Cholecalciferol increases bone turnover markers in humans.

    “In the 500,000 IU treatment group, PINP increased significantly from baseline at week 1 and remained higher than baseline at week 4.”

    Human trial3 months

    Effects of High Dose Bolus Cholecalciferol on Free Vitamin D Metabolites, Bone Turnover Markers and Physical Function

    Nutrients

  3. Cholecalciferol showed no clear effect on bone turnover markers in humans (healthy men with serum 25-hydroxyvitamin D levels <75 nmol/L) (p > 0.05).

    “vitamin D treatment for 12 weeks had no significant effect on BTMs or BMD.”

    Human trialhealthy men with serum 25-hydroxyvitamin D levels <75 nmol/L20,000 IU/week12 weeksmalesn = 192

    Effects of Vitamin D Supplementation on Bone Turnover and Bone Mineral Density in Healthy Men: A Post-Hoc Analysis of a Randomized Controlled Trial

    Nutrients

  4. Cholecalciferol showed no clear effect on bone turnover markers in humans (advanced heart failure) (all P values > 0.05).

    “BTMs were initially within their reference ranges and did not differ significantly between groups at study termination”

    Human trialadvanced heart failureblood4000 IU daily3 yearsmalesn = 158

    Vitamin D supplementation and bone turnover in advanced heart failure: the EVITA trial

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

  5. Cholecalciferol showed no clear effect on bone turnover markers in humans (Nursing home residents).

    “Bone turnover markers did not decrease.”

    Human trialNursing home residents4 months

    Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

  6. Cholecalciferol showed no clear effect on bone turnover markers in humans.

    “There was no significant effect of supplementation on bone turnover markers or PTH concentrations.”

    Human trial8 weeksn = 27

    Effect of vitamin D supplementation on vitamin D status and bone turnover markers in young adults

    European journal of clinical nutrition

  7. Cholecalciferol showed no clear effect on bone turnover markers in humans (calcium-replete).

    “There were no persistent changes in serum PTH levels or the markers of bone turnover”

    Human trialcalcium-replete20 to 50 microg/d3 yearsfemalesn = 208

    A randomized controlled trial of vitamin D3 supplementation in African American women

    Archives of internal medicine

More on Cholecalciferol

Collagen peptides

upin humans1downin humans1upin reviews1

3 studies
  1. Collagen peptides decrease bone turnover markers in humans with osteopenia.

    “prevention of aBMD decline and decrease of bone turnover after 12-mo supplementation with calcium, vitamin D with CPs.”

    Human trialwith osteopenia5 g CPs, 500 mg calcium and 400 IU vitamin D3 per day12-mofemales

    Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides on Volumetric and Areal Bone Mineral Density, Bone Geometry and Bone Turnover in Postmenopausal Women With Osteopenia

    Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry

  2. Collagen peptides improve bone turnover markers in human subjects, particularly postmenopausal women.

    “Collagen supplementation was associated with improvements in BTMs such as procollagen type I N-terminal propeptide and C-terminal telopeptide of type I collagen”

    Reviewin human subjects, particularly postmenopausal womencollagen peptides

    The Role of Collagen Supplementation in Bone Metabolism and Structure: A Scoping Review

    Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine

  3. Collagen peptides improve bone turnover markers (SMD 0.40–0.58).

    “Collagen had no noticeable variance (I2 = 0%) and enhanced bone turnover indicators (SMD 0.40-0.58) and muscle performance (SMD 0.60 [0.05, 1.15]).”

    Review

    Efficacy of collagen peptide supplementation on bone and muscle health: a meta-analysis

    Frontiers in nutrition

More on Collagen peptides

Denosumab

downin humans2

2 studies
  1. Denosumab decreases bone turnover markers.

    “After six months of denosumab treatment, significant reductions were observed in bone turnover markers compared to baseline: t-PINP (16.83±13.03 ng/mL; 95% CI: 33.89 to 45.71; P < 0.001), N-terminal mid-fragment osteocalcin (15.66±4.57 ng/mL; 95% CI: 6.64 to 14.48; P < 0.001), and β-CTx (0.14±0.05 ng/mL; 95% CI: 0.15 to 0.26; P < 0.001”

    Human trialone-year treatment coursen = 40

    Denosumab for Primary Osteoporosis and Its Impact on Sarcopenia in the Chinese Population: Insights from Clinical Evidence and RANKL Pathway Mendelian Randomization

    Clinical interventions in aging

  2. Denosumab decreases bone turnover markers in humans (P < 0.05).

    “Denosumab significantly reduced bone turnover markers”

    Human trial6 months

    Denosumab for Primary Osteoporosis and Its Impact on Sarcopenia in the Chinese Population: Insights from Clinical Evidence and RANKL Pathway Mendelian Randomization

    Clinical interventions in aging

  3. Denosumab decreases bone turnover markers in individuals at risk of fracture.

    “antiresorptive agents such as bisphosphonates and denosumab cause rapid alterations in BTMs, which correlate with long-term gains in BMD and reduced fracture risk.”

    Reviewin individuals at risk of fracture

    Clinical Significance of Bone Turnover Markers in Osteoporosis: Fracture Risk Assessment and Treatment Monitoring

    Journal of menopausal medicine

More on Denosumab

Vitamin D

no changein humans1upin humans1

2 studies
  1. Vitamin D showed no clear effect on bone turnover markers in humans (Comparison among supplement, fortified oil, and control groups).

    “The mean differences of PTH, BAP, and CTX were not significantly different among the study groups.”

    Human trialComparison among supplement, fortified oil, and control groupstablet or fortified canola oil1000 IU daily12 weeksn = 93

    Effects of vitamin D-fortified oil intake versus vitamin D supplementation on vitamin D status and bone turnover factors: A double blind randomized clinical trial

    Clinical nutrition ESPEN

  2. Vitamin D improves bone turnover markers in persons with epilepsy treated with antiepileptic drugs.

    “After vitamin D treatment, there appeared to be positive changes in bone turnover markers;”

    Reviewin persons with epilepsy treated with antiepileptic drugs

    Vitamin D supplementation for bone health in adults with epilepsy: A systematic review

    Epilepsia

More on Vitamin D

Semaglutide

no changein humans1

1 study
  1. Semaglutide showed no clear effect on bone turnover markers in humans (CTX and P1NP, compared with lifestyle counseling alone) (CTX p = 0.56; P1NP p = 0.78).

    “No significant differences in whole-body BMD (p = 0.77) or BTMs (CTX: p = 0.56, P1NP: p = 0.78) were observed between groups over time.”

    Human trialCTX and P1NP, compared with lifestyle counseling alonebone1.0 mg weekly20 weeksn = 20

    Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial post hoc analysis

    Frontiers in aging

  2. Semaglutide showed no clear effect on bone turnover markers in humans.

    “No significant changes in BTMs were observed in either group.”

    Human trial20 weeksn = 20

    Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial post hoc analysis

    Frontiers in aging

More on Semaglutide

Asparagus racemosus

no changein humans1

1 study
  1. Asparagus racemosus showed no clear effect on bone turnover markers in postmenopausal women (placebo −0.4 ± 8.7 μg/L, shatavari + 1.3 ± 6.5 μg/L).

    “Neither P1NP (placebo −0.4 ± 8.7 μg/L, shatavari + 1.3 ± 6.5 μg/L; p = 0.16, t-test), nor β-CTX (placebo +0.01 ± 0.11 μg/L, shatavari −0.08 ± 0.22 μg/L; p = 0.27, Mann–Whitney U), were altered by supplementation condition ( A,B).”

    Human trialin postmenopausal womensix weeksfemalesn = 24

    Shatavari Supplementation in Postmenopausal Women Improves Handgrip Strength and Increases Vastus lateralis Myosin Regulatory Light Chain Phosphorylation but Does Not Alter Markers of Bone Turnover

    Nutrients

  2. Asparagus racemosus showed no clear effect on bone turnover markers in humans (postmenopausal).

    “Shatavari supplementation did not alter plasma markers of bone turnover (P1NP, β-CTX)”

    Human trialpostmenopausalequivalent to 26,500 mg/d fresh weight shatavari1000 mg/d6 weeksfemalesn = 20

    Shatavari Supplementation in Postmenopausal Women Improves Handgrip Strength and Increases Vastus lateralis Myosin Regulatory Light Chain Phosphorylation but Does Not Alter Markers of Bone Turnover

    Nutrients

More on Asparagus racemosus

Blood flow restriction training

no changein reviews1

1 study
  1. Blood flow restriction training showed no clear effect on bone turnover markers.

    “No clear pooled effects were observed for acute or chronic bone turnover markers.”

    Reviewacute and chronic

    Acute responses and chronic effects of blood flow restriction training on bone-related outcomes: a systematic review and multilevel meta-analysis

    Frontiers in physiology

More on Blood flow restriction training

SGLT2 inhibitors

no changein humans1

1 study
  1. SGLT2 inhibitors were not clearly linked with bone turnover markers in postmenopausal women with type 2 diabetes.

    “Classical bone turnover markers (P1NP, CTX, coupling index) and DXA-derived BMD did not significantly differ between groups.”

    Humansin postmenopausal women with type 2 diabetesfemalesn = 23

    SGLT2 Inhibitors Are Associated With Suppression of the Sema3A/NRP1/Plexin-A1 Signaling Axis in Postmenopausal Women With Type 2 Diabetes: Evidence From Propensity Score-Matched Analysis

    Journal of diabetes

More on SGLT2 inhibitors

Bisphosphonates

downin humans1

1 study
  1. Bisphosphonates decrease bone turnover markers in individuals at risk of fracture.

    “antiresorptive agents such as bisphosphonates and denosumab cause rapid alterations in BTMs, which correlate with long-term gains in BMD and reduced fracture risk.”

    Reviewin individuals at risk of fracture

    Clinical Significance of Bone Turnover Markers in Osteoporosis: Fracture Risk Assessment and Treatment Monitoring

    Journal of menopausal medicine

More on Bisphosphonates

Lawsonia inermis

upin rats1

1 study
  1. Lawsonia inermis improves bone turnover markers in rats (ovariectomized rats).

    “favourably modulated bone turnover markers by decreasing tartrate-resistant acid phosphatase, parathyroid hormone and osteocalcin levels”

    Animalsovariectomized ratsethanolic leaf extractten weeksfemalesn = 8

    Anti-osteoporotic potential of Lawsonia inermis leaf extract: integration of network pharmacology, molecular docking, and experimental validation in ovariectomized rats

    Inflammopharmacology

More on Lawsonia inermis

Lacticaseibacillus paracasei + lactiplantibacillus plantarum

no changein humans1

1 study
  1. Lacticaseibacillus paracasei + lactiplantibacillus plantarum showed no clear effect on bone turnover markers in humans.

    “No treatment effects were observed for bone turnover, calciotropic, or inflammatory markers.”

    Human trial12 mofemalesn = 114

    Probiotic did not slow bone loss soon after menopause

    The American journal of clinical nutrition

More on Lacticaseibacillus paracasei + lactiplantibacillus plantarum

Metformin

no changein humans1

1 study
  1. Metformin showed no clear effect on bone turnover markers in humans (Treatment-naïve Saudi adults with newly diagnosed type 2 diabetes).

    “metformin-based interventions showed no significant effects on bone turnover markers.”

    Human trialTreatment-naïve Saudi adults with newly diagnosed type 2 diabetes1000 mg/day6 monthsn = 38

    Comparative effects of metformin and lifestyle therapy on bone metabolism markers: A 6-month pilot, open-label randomized-clinical trial

    Aging clinical and experimental research

More on Metformin

Dapagliflozin

no changein humans1

1 study
  1. Dapagliflozin showed no clear effect on bone turnover markers in humans (compared with placebo).

    “did not demonstrate any meaningful impact of dapagliflozin on either bone turnover or QCT markers”

    Human trialcompared with placebo10 mg daily12 months

    Impact of dapagliflozin on bone mineral metabolism in non-diabetic patients with chronic kidney disease: a randomized, double-blind, placebo-controlled study

    Clinical kidney journal

More on Dapagliflozin

Sitagliptin

no changein humans1

1 study
  1. Sitagliptin showed no clear effect on bone turnover markers in humans.

    “No significant differences were detected in other skeletal sites or bone turnover markers.”

    Human trial52 weeksfemalesn = 132

    Effect of sitagliptin vs. placebo on bone mineralization in women with type 2 diabetes: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) randomized clinical trial

    BMC medicine

More on Sitagliptin

Ashwagandha

downin humans1

1 study
  1. Ashwagandha decreases bone turnover markers in humans (postmenopausal) (P < 0.0001).

    “Women supplemented with Ws or Ar extracts had significantly decreased levels of the BTMs C-terminal telopeptide of type I collagen, bone alkaline phosphatase, and receptor activator of nuclear factor kappa-B ligand, and increased osteoprotegerin levels (P < 0.0001).”

    Human trialpostmenopausal24 weeksfemales

    Ashwagandha and Shatavari Extracts Dose-Dependently Reduce Menopause Symptoms, Vascular Dysfunction, and Bone Resorption in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Study

    Journal of menopausal medicine

More on Ashwagandha

All 32

Effects

4

Fracture risk prediction

no changein humans1

1 study
  1. Bone turnover markers were not clearly linked with fracture risk prediction in humans (alone or combined with miRNA ratios).

    “Adding bone turnover markers (BTMs), alone or in combination with miRNA ratios, did not yield any improvement in model performance”

    Humansalone or combined with miRNA ratiosserumfemalesn = 1,128

    MON-790 The Use Of Microrna Ratios To Predict Fractures In Older Women: The Opus Study

    ENDO 2025 abstract

Hip fracture

no changein humans1

1 study
  1. Bone turnover markers were not clearly linked with hip fracture in humans.

    “BTMs were not predictive for hip fractures.”

    Humansfemales

    Bone Turnover Marker Profiling and Fracture Risk in Older Women: Fracture Risk from Age 75 to 90

    Calcified tissue international

More on Hip fracture

Mortality

no changein humans1

1 study
  1. Bone turnover markers were not clearly linked with mortality in hemodialysis patients.

    “There were no associations between BTMs and mortality risk.”

    Humansin hemodialysis patients3.5 ± 1.0 yearsn = 164

    Role of Fracture Risk Assessment Tool and Bone Turnover Markers in Predicting All-Cause and Cardiovascular Mortality in Hemodialysis Patients

    Frontiers in medicine

Fracture risk

no changein humans1

1 study
  1. Bone turnover markers were not clearly linked with fracture risk in humans.

    “Markers were not associated with fracture risk.”

    HumansMedian 11.7 years (range 5.4–12.5)n = 1,069

    Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Upstream

7

Androgen-insensitivity syndrome

upin humans1

1 study
  1. Androgen-insensitivity syndrome is linked with higher bone turnover markers in humans (compared with age-matched controls).

    “Bone turnover markers resulted increased compared with age-matched controls.”

    Humanscompared with age-matched controlsfemalesn = 46

    Bone health in complete androgen insensitivity syndrome: a comprehensive assessment in a large adult cohort

    European journal of endocrinology

More on Androgen-insensitivity syndrome

Vitamin K status

no changein humans1

1 study
  1. Vitamin K status showed no clear effect on bone turnover markers in humans.

    “no significant interaction between vitamin K status and the intervention (vitamin D supplementation/placebo) on cardiovascular or bone parameters”

    Human trial2,800 international units daily8 weeksn = 200

    Vitamin K status has no influence on the effect of vitamin D supplementation on bone turnover and cardiovascular markers: a randomized controlled trial

    Frontiers in nutrition

More on Vitamin K status

GDF-15

no changein humans1

1 study
  1. GDF-15 was not clearly linked with bone turnover markers in each age group.

    “We did not find any significant correlation between GDF 15 and bone turnover markers (BTMs), BMD, HRpQCT measures and hormones in any of the age groups.”

    Humansin each age group

    Effect of age and gender on serum growth differentiation factor 15 and its relationship to bone density and bone turnover

    Bone reports

More on GDF-15

Age

downin cynomolgus monkeys1

1 study
  1. Age decreases bone turnover markers in cynomolgus monkeys.

    “Osteocalcin, and C-Terminal Telopeptide Of Type I Collagen peaked at 1 to 3 years of age and gradually decreased with age”

    Animalsserum procollagen I aminoterminal propeptide, bone alkaline phosphatase, osteocalcin and C-terminal telopeptide of type I collagenfemales

    Analysis of serum bone turnover markers in female cynomolgus monkeys of different ages

    Frontiers in endocrinology

TBS Hip

no changein humans1

1 study
  1. TBS Hip was not clearly linked with bone turnover markers in humans (residents of long-term care facilities) (not statistically significant).

    “There was no statistically significant correlation between BTMs with TBS at lumbar spine or TBS Hip at total hip, femoral neck, and greater trochanter.”

    Humansresidents of long-term care facilitiesfemalesn = 132

    Trabecular bone score in the hip: a new method to examine hip bone microarchitecture-a feasibility study

    Archives of osteoporosis

More on TBS Hip

Homocysteine

no changein humans1

1 study
  1. Homocysteine showed no clear effect on bone turnover markers in humans (low homocysteine concentrations).

    “most studies have reported the lack of an effect of low homocysteine concentrations on bone turnover markers, bone mineral density or fracture risks.”

    Reviewlow homocysteine concentrationsbone

    B vitamins and homocysteine as determinants of bone health: A literature review of human studies

    Journal of human nutrition and dietetics : the official journal of the British Dietetic Association

More on Homocysteine

Postmenopausal-women

upin humans1

1 study
  1. Postmenopausal-women increases bone turnover markers in humans (estrogen withdrawal).

    “biochemical markers of bone turnover markedly increase in postmenopausal women, indicating accelerated bone remodeling because of estrogen withdrawal.”

    Reviewestrogen withdrawal

    Calcium and bone metabolism across women's life stages. Changes of biochemical markers of bone turnover in life cycle of women

    Clinical calcium

Associations

21

MXRA7 expression

downin humans1

1 study
  1. MXRA7 expression is associated with bone turnover markers in humans (Osteoporosis).

    “MXRA7 expression was significantly negatively correlated with OC, PINP, and β-CTX levels”

    HumansOsteoporosisserum

    Significance of matrix remodeling associated 7 expression in senile osteoporosis

    Chinese Journal of Osteoporosis

More on MXRA7 expression

Lipid and ceramide metabolism

mixedin humans1

1 study
  1. Lipid and ceramide metabolism is associated with bone turnover markers in women living with HIV.

    “Bone turnover markers were associated with metabolites significantly enriched in multiple metabolic pathways, including PUFA and other lipid metabolic pathways”

    Humansin women living with HIVplasmafemales

    Plasma polyunsaturated fatty acid metabolism associations with bone mineral density and bone turnover in pre- and postmenopausal women living with HIV

    Clinical nutrition ESPEN

More on Lipid and ceramide metabolism

Vitamin D deficiency

upin humans1

1 study
  1. Vitamin D deficiency is associated with bone turnover markers in hip fracture patients.

    “Patients with VDD showed higher levels of bone turnover markers.”

    Humansin hip fracture patientsn = 934

    Prevalence, predictors, and clinical impact of vitamin D deficiency on 12-month outcomes in hip fracture patients

    Journal of endocrinological investigation

More on Vitamin D deficiency

Kidney failure

upin humans1+53%

1 study
  1. Kidney failure is associated with bone turnover markers in humans (dialysis / kidney failure) (53%).

    “bone turnover markers suggested high bone turnover in 53% of patients.”

    Humansdialysis / kidney failuren = 71

    Therapeutic opportunities for CKD-associated osteoporosis in adults with kidney failure imply screening

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

More on Kidney failure

Metabolic dysfunction-associated steatotic liver disease

downin humans1

1 study
  1. Metabolic dysfunction-associated steatotic liver disease is associated with bone turnover markers in humans (WMD: -0.03 ng/mL, 95% CI: -0.05 to -0.02, P<0.001).

    “decreased BTMs (CTX: WMD: -0.03 ng/mL, 95% CI: -0.05 to -0.02, P<0.001”

    Review

    Association of metabolic dysfunction-associated steatotic liver disease with bone health in adults: a systematic review and meta-analysis of observational studies

    Frontiers in endocrinology

More on Metabolic dysfunction-associated steatotic liver disease

ADRB1, ADRB2, and HDAC4 variants

mixedin humans1

1 study
  1. ADRB1, ADRB2, and HDAC4 variants are associated with bone turnover markers in humans (Pharmacogenetic effects during beta blocker treatment in postmenopausal women).

    “We discovered several variants in ADRB1, ADRB2, and HDAC4 which showed significant pharmacogenetic effects with BMD at multiple sites and with BTMs.”

    Human trialPharmacogenetic effects during beta blocker treatment in postmenopausal womenbone20 weeksfemales

    Pharmacogenetic and microRNA mechanisms of beta blocker use on bone

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Low-density lipoprotein and high-density lipoprotein triglyceride content and high-density lipoprotein Apo-A2 content

downin humans1

1 study
  1. Low-density lipoprotein and high-density lipoprotein triglyceride content and high-density lipoprotein Apo-A2 content is associated with bone turnover markers in humans.

    “The triglyceride content in low-density lipoprotein and high-density lipoprotein particles and the Apo-A2 content in high-density lipoprotein particles was further inversely associated with the BTMs.”

    Humansserum

    Bone turnover: the role of lipoproteins in a population-based study

    Lipids in health and disease

More on Low-density lipoprotein and high-density lipoprotein triglyceride content and high-density lipoprotein Apo-A2 content

Very-low-density lipoprotein and intermediate-density lipoprotein triglyceride and cholesterol content

downin humans1

1 study
  1. Very-low-density lipoprotein and intermediate-density lipoprotein triglyceride and cholesterol content is associated with bone turnover markers in humans.

    “The triglyceride or cholesterol content in very-low-density lipoprotein and intermediate-density lipoprotein particles was inversely associated with both BTMs”

    Humansserum

    Bone turnover: the role of lipoproteins in a population-based study

    Lipids in health and disease

More on Very-low-density lipoprotein and intermediate-density lipoprotein triglyceride and cholesterol content

Fasting glucose

upin humans1

1 study
  1. Bone turnover markers are associated with fasting glucose in humans (Cross-sectional analysis).

    “lower levels of circulating bone turnover markers and higher BMD were significantly associated with increased fasting glucose and HbA1c levels.”

    HumansCross-sectional analysisn = 993

    Association of Bone Mineral Density and Bone Turnover Markers with the Risk of Diabetes: Hong Kong Osteoporosis Study and Mendelian Randomization

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

More on Fasting glucose

Body weight

downin humans1

1 study
  1. Body weight is associated with bone turnover markers in humans (heavier versus leaner monozygotic co-twins).

    “heavier co-twins had higher lumbar vertebral BM GU (p < .001) and lower bone turnover markers (all p < .01) compared with leaner co-twins”

    Humansheavier versus leaner monozygotic co-twinsbaseline

    Bone marrow metabolism is affected by body weight and response to exercise training varies according to anatomical location

    Diabetes, obesity & metabolism

Cannabidiol

downin humans1

1 study
  1. Cannabidiol is associated with bone turnover markers in humans (Postmenopausal women with osteopenia; comparison with baseline) (100 and 300 mg daily, respectively: CTx −8.5%, −28.1%; P1NP −9.9%, −39.5%; BSAP −12.7%, −74.8%; OC −16.0%, −6.7% versus baseline).

    “was associated with reduction in measured markers of bone turnover.”

    Human trialPostmenopausal women with osteopenia; comparison with baseline100 or 300 mg daily12 weeksfemalesn = 2

    Oral Cannabidiol Treatment in Two Postmenopausal Women with Osteopenia: A Case Series

    Cannabis and cannabinoid research

More on Cannabidiol

All 21

Latest

Dec 2025: 11Jan 2026: 13Feb 2026: 13Mar 2026: 15Apr 2026: 17May 2026: 11Jun 2026: 11Jul 2026: 5Aug 2026: 19Sep 2026: 13Oct 2026: 12Nov 2026: 7147 papers in 12 months
medRxiv

Loneliness linked to poorer bone health in older men

Loneliness was linked to higher fracture odds in men, with an odds ratio of 2.46, but not women, in a prospective cohort of 2,850 adults.Loneliness was linked to higher fracture odds in men, with an odds ratio of 2.46, but not women, in a prospective cohort of 2,850 adults.

Preprint: cohort · 2,850 peopleBones and joints

See all 434 papers on bone turnover markers